TRUSTED BY GLOBAL SPONSORS AND CROS
Delivering Global Research Standards with Local Expertise
Faster Startup
Reduce regulatory bottlenecks with our pre-vetted network of research-ready sites in Kenya and Rwanda, designed for rapid study activation.
Quality Delivery
Consistent, GCP-compliant execution through standardized protocols and robust oversight across diverse therapeutic areas.
Cost Efficiency
Optimized operational infrastructure and integrated site management reduce clinical trial costs while maintaining elite ethical standards.
Strategic Network Footprint Across Kenya & Rwanda
CREA-N delivers operational excellence through a robust network of research-ready sites strategically located in key regions of Kenya and Rwanda. We provide the infrastructure and clinical expertise needed to deliver ethical, high-quality trials that bridge the global representation gap. Our footprint ensures Sponsors and CROs have access to diverse populations through inclusive and efficient drug development pathways across the East African region.
Diverse Therapeutic Expertise
Infectious Diseases
Oncology & Cancer Research
Cardiovascular Health
Metabolic & Diabetes
Maternal & Child Health
Respiratory Health
5+
RESEARCH-READY SITES
2
COUNTRIES IN NETWORK
30+
CLINICAL RESEARCHERS
Multi
THERAPEUTIC EXPERTISE
Empowering Global Clinical Success
Operational Speed and Regulatory Agility
We bridge the gap between protocol approval and site activation by leveraging deep regional expertise and established networks. Our processes ensure faster startup times for phase II-IV trials by anticipating local regulatory requirements.
Global Quality, Local Relevance
The data integrity of our network is absolute. We implement rigorous ICH-GCP compliant frameworks that integrate seamlessly with international drug development standards, offering sponsors total confidence in every trial outcome.
Inclusivity Through Infrastructure
We bring global clinical research to new populations through a model that prioritizes community engagement and sustainable local investment. This approach ensures trials are ethical, inclusive, and scientifically robust.